Here are the 424B prospectus supplements from Citius Pharmaceuticals Inc. (CTXR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CTXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTXR filings page.
Citius Pharmaceuticals is registering 4,730,457 shares of common stock and pre-funded warrants to purchase up to 345,686 shares. The shares are being sold at $0.985 per share and the Pre-funded Warrants at $0.9849 each, with the Pre-funded Warrants exercisable for $0.0001 per share.
The offering includes a concurrent private placement of Common Warrants to purchase up to 5,076,143 shares exercisable at $0.86 (not registered here). Net proceeds to the company are estimated at approximately $4.5 million after placement agent fees. Closing is anticipated on or about April 24, 2026, subject to customary conditions.